Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair. Our approach to drug discovery is driven by deep scientific expertise—and an urgency to deliver effective treatments to thousands of patients who have few or no therapeutic options. The Company’s lead product candidate, luspatercept, is a first-in-class erythroid (red blood cell) maturation agent (EMA) being developed to treat patients who have serious blood disorders marked by a late-stage defect in the maturation of red blood cells. Alongside our partner Celgene—a leader in hematology—we are advancing multiple Phase 2 and Phase 3 trials of luspatercept in five target indications across myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing a neuromuscular program with a locally-acting “Myostatin+” agent, ACE-083. We recently initiated a Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH). Acceleron has ongoing preclinical research efforts targeting additional indications in these three disease areas in which there is high unmet medical need. Source
No articles found.
Following two acquisitions of Creagh Medical and NorMedix – recognized innovators ...
Following two acquisitions of Creagh Medical an...
Cyndescope Inc. is a technology company focusing on software solutions for the hea...
Cyndescope Inc. is a technology company focusin...
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.